<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FT944-1392</title>
	</head>
	<body>
		<main>
			<p>941220 FT  20 DEC 94 / International Company News: Fisons and RPR abandon US venture Rhone-Poulenc Rorer (RPR), the drugs arm of French chemicals company Rhone-Poulenc, and Fisons of the UK, have abandoned a pharmaceuticals sales joint venture in the US. Fisons' most important drug, asthma treatment Tilade, and RPR's Azmacort will now no longer be sold by each others' sales teams. Fisons said yesterday the change followed the transformation in the US healthcare market, where individual doctors are being replaced as drug buyers by health management organisations. RPR and Fisons have a marketing agreement in Europe.</p>
		</main>
</body></html>
            